Your Guide to Peptide Research

A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.

A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.

A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.

A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that statins and PCSK9 inhibitors can't touch. Zerlasiran, a long-acting siRNA from Silence Therapeutics, cut Lp(a) by more than 80% with dosing as infrequent as every 16–24 weeks. Here's how it works, what its Phase 2 ALPACAR-360 trial showed, and why its Phase 3 is on hold.

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Lepodisiran, a long-duration siRNA from Eli Lilly, silences the gene behind it and cut Lp(a) by nearly 94% in Phase 2 — with a single shot lasting a year or more. Its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes study to include people who haven't yet had a cardiovascular event.

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Olpasiran, an siRNA from Amgen, silences the gene behind it and cuts Lp(a) by up to ~97% with a shot every 12 weeks. Its Phase 3 OCEAN(a)-Outcomes trial (~7,000 patients) is one of the pivotal 2026 readouts testing whether lowering Lp(a) actually prevents cardiovascular events.